Setback in Indian Court Compounds Challenges for Novo Nordisk
Published on 12/07/2025 at 12:56 | Redaktion boerse-global.de
Novo Nordisk faces mounting headwinds as a recent legal decision in India deals a blow to its patent strategy. A Delhi court has denied the Danish pharmaceutical giant’s request for an interim injunction against competitor Dr. Reddy’s Laboratories, permitting the continued export of semaglutid. This ruling weakens Novo Nordisk’s patent protection in key markets, arriving during a period of significant pressure on the company’s share price.
The court’s refusal to block Dr. Reddy’s allows the Indian firm to keep manufacturing and exporting semaglutid—the active ingredient in blockbuster drugs Ozempic and Wegovy—to nations where Novo Nordisk does not hold enforceable patents. While Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
